Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to 0.06.

  • Intellia Therapeutics' Asset Utilization Ratio rose 7309.66% to 0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06, marking a year-over-year increase of 7309.66%. This contributed to the annual value of 0.05 for FY2024, which is 8062.13% up from last year.
  • As of Q3 2025, Intellia Therapeutics' Asset Utilization Ratio stood at 0.06, which was up 7309.66% from 0.06 recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Asset Utilization Ratio high stood at 0.07 for Q1 2021, and its period low was 0.02 during Q3 2021.
  • Moreover, its 5-year median value for Asset Utilization Ratio was 0.04 (2022), whereas its average is 0.04.
  • Its Asset Utilization Ratio has fluctuated over the past 5 years, first tumbled by 8271.24% in 2021, then surged by 13633.37% in 2022.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Asset Utilization Ratio stood at 0.02 in 2021, then skyrocketed by 101.23% to 0.04 in 2022, then fell by 28.75% to 0.03 in 2023, then skyrocketed by 71.69% to 0.05 in 2024, then grew by 28.83% to 0.06 in 2025.
  • Its Asset Utilization Ratio was 0.06 in Q3 2025, compared to 0.06 in Q2 2025 and 0.04 in Q1 2025.